» Articles » PMID: 18372921

EGFR Somatic Doublets in Lung Cancer Are Frequent and Generally Arise from a Pair of Driver Mutations Uncommonly Seen As Singlet Mutations: One-third of Doublets Occur at Five Pairs of Amino Acids

Overview
Journal Oncogene
Date 2008 Apr 1
PMID 18372921
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Doublet mutations in cancer are not well studied. We find that allelic somatic doublet mutations are present at high frequency in the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) domain in lung cancers. When doublets from the literature are added, a total of 96 doublets are available for analysis. The frequency of doublets overall is 6%, which is sevenfold greater than that observed in normal tissue in mouse. All characterized doublets are allelic, and silent mutations occur rarely. About half of all doublets contain one or two of 12 distinct missense mutations at five amino acids: E709, G719, S768, T790 and L861. The mutations at these five amino acids are seldom reported as singlets. Moreover, when the common L858 target is included, more than one-third of EGFR doublets are one of five specific missense pairs: G719/E709, G719/S768, G719/L861, L858/E709 and L858/T790. Structure suggests function: The data imply that most EGFR doublets are NOT consistent with a 'driver and passenger' mutation mechanism. EGFR doublets are highly skewed relative to singlets, consistent with functional selection of two individually suboptimal mutations that, in combination, have enhanced oncogenic potential.

Citing Articles

An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations.

Chakroborty D, Ojala V, Knittle A, Drexler J, Tamirat M, Ruzicka R Cancer Res Commun. 2023; 2(1):10-27.

PMID: 36860695 PMC: 9973412. DOI: 10.1158/2767-9764.CRC-21-0021.


Pan-cancer clinical impact of latent drivers from double mutations.

Yavuz B, Tsai C, Nussinov R, Tuncbag N Commun Biol. 2023; 6(1):202.

PMID: 36808143 PMC: 9941481. DOI: 10.1038/s42003-023-04519-5.


Complex mutations in non-small cell lung cancer: a distinct entity?.

Bienkowski M, Dziadziuszko R, Jassem J J Thorac Dis. 2022; 14(8):2738-2741.

PMID: 36071780 PMC: 9442527. DOI: 10.21037/jtd-2022-05.


Gefitinib-induced hemorrhagic cystitis and inflammatory contracted bladder in a patient with advanced lung adenocarcinoma harboring compound epidermal growth factor receptor G719S and S768I missense mutations: a case report.

Bai X, Cheng J, Zhao L, Cheng M Ann Transl Med. 2022; 10(14):809.

PMID: 35965829 PMC: 9372651. DOI: 10.21037/atm-22-3233.


mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors.

Liu Y, Wang H, Yang S, Yang Y, Wu Y, He Z J Thorac Dis. 2022; 14(6):2254-2267.

PMID: 35813717 PMC: 9264099. DOI: 10.21037/jtd-22-755.